• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Dulera (mometasone furoate + formoterol fumarate dihydrate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Dulera (mometasone furoate + formoterol fumarate dihydrate)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Dulera Inhalation Aerosal is a fixed-dose combination of the inhaled corticosteroid mometasone furoate plus the long-acting beta2-agonist formoterol fumarate dihydrate.

    Dulera is specifically indicated for the treatment of asthma in patients 12 years of age and older.

    Dulera is supplied as as an inhalation aerosal. The recommended starting dosages for Dulera treatment are based on prior asthma therapy.
    Previous Therapy: Inhaled medium dose corticosteroids Recommended Dose: 100 mcg/5 mcg, 2 inhalations twice daily Maximum Recommended Daily Dose: 400 mcg/20 mcg
    Previous Therapy: Inhaled high dose corticosteroids Recommended Dose: 200 mcg/5 mcg, 2 inhalations twice daily Maximum Recommended Daily Dose: 800 mcg/20 mcg

    Clinical Results

    FDA Approval
    The FDA approval of Dulera was partially based on two randomized clinical trials (Trial 1, Trial 2). These trials enrolled a total of 1,509 patients 12 years of age and older with persistent asthma uncontrolled on medium or high dose inhaled corticosteroids. These studies included a 2 to 3-week run-in period with mometasone furoate to establish a certain level of asthma control. Trial 1 compared Dulera 100 mcg/5 mcg to its individual components, mometasone furoate 100 mcg and formoterol 5 mcg, and placebo). Trial 2 compared Dulera 200 mcg/5 mcg with Dulera 100 mcg/5 mcg and mometasone furoate 200 mcg. All medications were given as two inhalations twice daily by metered dose inhalers. In both trials Dulera resulted in significant improvement from baseline in lung function (mean area under the concentration-time curve for forced expiratory volume in 1 second, measured from 0 to 12 hours [FEV1 AUC0-12h]) at week 12, a primary efficacy endpoint, compared to mometasone furoate (Trial 1 and 2) and placebo (Trial 1). In Trial 1, these differences were maintained through week 26. The change in mean trough FEV1 from baseline to week 12 was assessed as another endpoint in both trials. In Trial 1, a significantly greater increase in the mean trough FEV1 was observed for Dulera 100 mcg/5 mcg compared to formoterol 5 mcg (the primary treatment comparison) as well as to placebo. In trial 2, a greater numerical increase in the mean trough FEV1 were was observed for Dulera 200 mcg/5 mcg compared to Dulera 100 mcg/5 mcg and mometasone furoate 200 mcg.

    Side Effects

    Adverse events associated with the use of Dulera may include, but are not limited to, the following:

    • Nasopharyngitis
    • Sinusitis
    • Headache

    Mechanism of Action

    Dulera Inhalation Aerosal is a fixed-dose combination of the inhaled corticosteroid mometasone furoate plus the long-acting beta2-agonist formoterol fumarate dihydrate.

    Additional Information

    For additional information regarding Dulera or asthma, please visit the Dulera web page.

    Approval Date: 2010-06-01
    Company Name: Merck
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing